Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Chung-Fan Yang

Nivolumab Plus Carboplatin and Paclitaxel as the First-Line Therapy for Advanced Squamous Cell Carcinoma of the Lung With Strong Programmed Death-Ligand 1 Expression: A Case Report

Cureus

2019

English

Leukoerythroblastosis in Castration-Resistant Prostate Cancer: A Clue to Diffuse Bone Marrow Carcinomatosis

Clinics and Practice

2019

English

Related publications

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers

Archives of Medical Science

Medicine

2014

English

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology

English

P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology

English

The Expression of Programmed Death Ligand-1 Within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Journal of Advances in Medicine and Medical Research

2020

English

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

English

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of Thoracic Oncology

English

Programmed Death-Ligand 1 Expression Correlates With Diminished CD8+ T Cell Infiltration and Predicts Poor Prognosis in Anal Squamous Cell Carcinoma Patients

Cancer Management and Research

Oncology

2017

English

Inflammation Promotes Oral Squamous Carcinoma Immune Evasion via Induced Programmed Death Ligand‑1 Surface Expression

English

A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Chung-Fan Yang

Nivolumab Plus Carboplatin and Paclitaxel as the First-Line Therapy for Advanced Squamous Cell Carcinoma of the Lung With Strong Programmed Death-Ligand 1 Expression: A Case Report

Leukoerythroblastosis in Castration-Resistant Prostate Cancer: A Clue to Diffuse Bone Marrow Carcinomatosis

Related publications

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

The Expression of Programmed Death Ligand-1 Within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Programmed Death-Ligand 1 Expression Correlates With Diminished CD8+ T Cell Infiltration and Predicts Poor Prognosis in Anal Squamous Cell Carcinoma Patients

Inflammation Promotes Oral Squamous Carcinoma Immune Evasion via Induced Programmed Death Ligand‑1 Surface Expression

A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer